Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Kidney J
Main Authors: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
CKD-Mdb
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://ncbi.nlm.nih.gov/pubmed/32082556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados